Stockscreener 앱 받기
226.22
1.27%
-2.91
시장 영업 전:
226.00
-0.22
-0.10%
전일 마감가:
$229.13
열려 있는:
$227.2
하루 거래량:
5.66M
Relative Volume:
1.05
시가총액:
$399.63B
수익:
$58.33B
순이익/손실:
$3.73B
주가수익비율:
107.66
EPS:
2.1013
순현금흐름:
$18.24B
1주 성능:
-2.17%
1개월 성능:
+3.96%
6개월 성능:
+27.95%
1년 성능:
+17.91%
1일 변동 폭
$225.32
$228.95
1주일 범위
$225.32
$234.68
52주 변동 폭
$163.81
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
226.22 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
826.57 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.17 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
NVS
Novartis Ag Adr
|
129.97 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.11 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AbbVie's Bretisilocin Hit With Enveric IP Claim - Yahoo
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 - GlobeNewswire Inc.
Can AbbVie Inc. stock outperform in 2025 bull marketFed Meeting & Daily Oversold Bounce Ideas - newser.com
Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie - GuruFocus
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisiloc - PharmiWeb.com
AbbVie breaks ground on new API manufacturing plant in North Chicago - Chicago Construction News
AbbVie could face patent battle over depression asset gained in Gilgamesh deal - Seeking Alpha
Enveric contests patent review petition related to AbbVie acquisition - Investing.com
AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Breti - GuruFocus
Top Medical Aesthetics Companies in 2025 - vocal.media
AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump - Yahoo Finance
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie? - The Globe and Mail
Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades' - Benzinga
Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally? - Yahoo Finance
Abbvie gets USFDA approval for updated indication statement for Rinvoq for Inflammatory Bowel Disease - Medical Dialogues
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Cr - GuruFocus
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colit - GuruFocus
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug - Stocktwits
FDA approves updated indication for AbbVie’s RINVOQ in IBD treatment - Investing.com
Use after 1 approved systemic therapy — AbbVie gets FDA approval to update RINVOQ IBD label allowing pre‑TNF use - Stock Titan
2 Dividend Stocks to Double Up on Right Now - The Globe and Mail
Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - MarketScreener
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - Investing News Network
AbbVie (ABBV) to Present New Antibody-Drug Conjugate Data at ESM - GuruFocus
Atria Wealth Solutions Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Envestnet Portfolio Solutions Inc. - MarketBeat
Concord Asset Management LLC VA Purchases 1,691 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Vest Financial LLC - MarketBeat
Griffin Asset Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
M.E. Allison & CO. Inc. Has $466,000 Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by MOKAN Wealth Management Inc. - MarketBeat
AbbVie Inc. $ABBV is Welch Group LLC's 9th Largest Position - MarketBeat
Almanack Investment Partners LLC. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Criteria Caixa S.A.U. Sells 47,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Cwm LLC Has $60.03 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
Vanguard Personalized Indexing Management LLC Acquires 37,680 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by OFI Invest Asset Management - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Buys Shares of 23,920 AbbVie Inc. $ABBV - MarketBeat
Sather Financial Group Inc Purchases New Position in AbbVie Inc. $ABBV - MarketBeat
2,500 Shares in AbbVie Inc. $ABBV Bought by Summa Corp. - MarketBeat
Johnson Investment Counsel Inc. Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades - Yahoo Finance
AbbVie Inc. $ABBV Holdings Lowered by Natural Investments LLC - MarketBeat
Fifth Third Wealth Advisors LLC Sells 4,542 Shares of AbbVie Inc. $ABBV - MarketBeat
One Degree Advisors Inc Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Conning Inc. - MarketBeat
Drucker Wealth 3.0 LLC Purchases 2,817 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Eastern Bank - MarketBeat
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.22%
자본화:
|
볼륨(24시간):